Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Effect of Atenativ Treatment on Uterine Blood Flow and the Amount of Atenativ Needed to Maintain a Normal Antithrombin Lvels During Two Weeks in Early and Severe Preeclampsia

NCT02278575 is registered in ClinicalTrials.gov with Vastra Gotaland Region as lead sponsor.

NCT NCT02278575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02278575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Effect of Atenativ Treatment on Uterine Blood Flow and the Amount of Atenativ Needed to Maintain a Normal Antithrombin Lvels During Two Weeks in Early and Severe Preeclampsia
Lead sponsor
Vastra Gotaland Region
Phase
Phase 4
Overall status
Withdrawn
Start date
January 31, 2016
Completion date
May 31, 2017
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antithrombin iii deficiency